New Long-term Data Demonstrate Patients with Mild Heart Failure Sustained Lower Mortality Rates After Receiving Boston Scientific CRT Defibrillators

[PR Newswire] – NATICK, Mass., March 30, 2014 /PRNewswire/ — In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation’s (BSX) exclusively sponsored and landmark Multicente more

View todays social media effects on BSX

View the latest stocks trending across Twitter. Click to view dashboard

See who Boston is hiring next, click here to view